Clinical implications for BRCA gene mutation in breast cancer

Molecular Biology Reports

Volumn 39, Issue 3, 2012, Pages 3097-3102

  Xu, Jin ^a   Wang, Baosheng ^a   Zhang, Yanjun ^a   Li, Ruihui ^b   Wang, Yuehua ^b   Zhang, Shaokun ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Basic Medical College   (China)

Author keywords

BRCA gene; Breast cancer; Molecular marker; Survival

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BRCA GENE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MUTATIONAL ANALYSIS; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; BREAST NEOPLASMS; CHINA; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; MUTATION; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84863829373     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-1073-y     Document Type: Article

References (21)

1. Pluta RM, Golub RM (2011) JAMA patient page. BRCA genes and breast cancer. JAMA 305(21):2244
2. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343:692-695
3. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282-4288
4. Pruthi S, Gostout BS, Lindor NM (2010) Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clin Proc 85:1111-1120
5. Wu M, Mao C, Chen Q, Cu XW, Zhang WS (2010) Serum p53 protein and anti-p53 antibodies are associated with increased cancer risk: a case-control study of 569 patients and 879 healthy controls. Mol Biol Rep 37(1):339-343
6. Takano EA, Mitchell G, Fox SB, Dobrovic A (2008) Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis. BMC Cancer 8:59
7. He P, Zhu D, Hu JJ, Peng J, Chen LS, Lu GX (2010) pcDNA3.1 (-)-mediated ribozyme targeting of HER-2 suppresses breast cancer tumor growth. Mol Biol Rep 37(3):1597-1604
8. Kirk R (2010) Surgical oncology: cancer risk reduction in BRCA mutation carriers. Nat Rev Clin Oncol 7:609
9. Han SH, Lee KR, Lee DG, Kim BY, Lee KE, Chung WS (2006) Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer. Clin Genet 70:496-501
10. Maegawa RO, Tang SC (2010) Triple-negative breast cancer: unique biology and its management. Cancer Invest 28:878-883
11. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Narod SA, Lubinski J, Polish Hereditary Breast Cancer Consortium (2008) Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 108:289-296
12. Goffin JR, Chappuis PO, Bégin LR, Wong N, Brunet JS, Hamel N, Paradis AJ, Boyd J, Foulkes WD (2003) Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 97:527-536
13. Moller P, Borg A, Evans DG, Haites N, Reis MM, Vasen H, Anderson E, Steel CM, Apold J, Goudie D, Howell A, Lalloo F, Maehle L, Gregory H, Heimdal K (2002) Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 101:555-559
14. Musolino A, Bella MA, Bortesi B, Michiara M, Naldi N, Zanelli P, Capelletti M, Pezzuolo D, Camisa R, Savi M, Neri TM, Ardizzoni A (2007) BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Breast 16:280-292
15. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Bégin LR, Offit K, Foulkes WD (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8-R17
16. El-Tamer M, Russo D, Troxel A, Bernardino LP, Mazziotta R, Estabrook A, Ditkoff BA, Schnabel F, Mansukhani M (2004) Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol 11:157-164
17. Brekelmans CT, Seynaeve C, Menke-Pluymers M, Bruggenwirth HT, Tilanus-Linthorst MM, Bartels CC, Kriege M, van Geel AN, Crepin CM, Blom JC, Meijers-Heijboer H, Klijn JG (2006) Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 17:391-400
18. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H et al (2000) Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 18:4053-4059
19. Eerola H, Vahteristo P, Sarantaus L, Kyyronen P, Pyrhonen S, Blomqvist C, Pukkala E, Nevanlinna H, Sankila R (2001) Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland. Int J Cancer 93:368-372
20. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115-123
21. Hartman AR, Ford JM (2003) BRCA1 and p53: compensatory roles in DNA repair. J Mol Med 81(11):700-707